Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations
NCT: NCT07598357 · NOT_YET_RECRUITING
Brief Summary
The purpose of this study is to prospectively study the safety of salvage red blood cell (sRBC) transfusion during pancreatic surgery. Primary Objective: 1. To summarize rates and timing of septic adverse events (AE) for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 2. To summarize rates and timing of transfusion related AEs for patients who receive sRBC or aRBC transfusions within 72 hours of peri-operative transfusion. 3. To summarize rates and timing of AEs in the first 7 post-operative days. Secondary Objectives: 1. To summarize the number of units of aRBC transfused post operative day (POD) #0 after sRBC transfusion in the operating room. 2. To summarize the number of units of aRBC transfused POD#1-7 after sRBC transfusion the operating room, in the absence of overt post-operative hemorrhage.
Frequently Asked Questions
What is Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations?
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations is a clinical trial registered under NCT07598357. Current status: NOT_YET_RECRUITING.
What is the status of NCT07598357?
The current status of NCT07598357 (Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations) is: NOT_YET_RECRUITING.
When did Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations start?
Salvaged Red Blood Cell Transfusion During Pancreatic Adenocarcinoma Operations started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.